SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.
Strategic Response to Market Valuation Trends
With recent volatility affecting its share price, Globus Medical views this repurchase authorization as a proactive measure to align its market valuation with its intrinsic business strength. Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical, stated, “We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation. Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforces our commitment to delivering long-term value to our shareholders.”
Flexible and Disciplined Capital Allocation Strategy
The company confirmed that the timing and total volume of repurchases will be determined by management, factoring in various considerations such as prevailing market prices, overall business conditions, legal requirements, and other investment opportunities. The program supports Globus Medical’s disciplined capital allocation approach, which remains focused on prioritizing long-term business growth while maintaining financial flexibility.
Key aspects of the program include:
- Execution through open market purchases or privately negotiated transactions.
- Potential utilization of trading plans under Rule 10b5-1 and/or Rule 10b-18 of the Securities Exchange Act of 1934.
- No set expiration date, allowing for suspension or discontinuation as deemed necessary.
- Funding of the repurchases through existing cash reserves.
Reinforcing Market Confidence Amid Industry Dynamics
This share buyback initiative highlights Globus Medical’s strategic positioning in the evolving musculoskeletal industry. By leveraging its financial strength, the company aims to enhance shareholder returns while continuing its investment in innovative product development and global market expansion.
As a company dedicated to solving unmet clinical needs, Globus Medical remains committed to advancing care in spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. The ongoing share repurchase program is expected to support these objectives by fostering a stable capital structure and reinforcing investor confidence.
A Commitment to Growth and Value Creation
Globus Medical’s announcement comes at a time when the broader medtech sector is experiencing shifts in market dynamics and investor expectations. By authorizing this significant repurchase program, the company signals its strong belief in the underlying value of its business and its unwavering focus on delivering both operational excellence and shareholder value.
Learn more at www.globusmedical.com